Use of antibodies and immunoconjugates for the therapy of more accessible cancers

Advanced Drug Delivery Reviews

Volumn 60, Issue 12, 2008, Pages 1407-1420

  Sharkey, Robert M ^a   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Antibody drug conjugates; Antibody toxin conjugates; Immunotherapy; Pretargeting; Radioimmunotherapy

Indexed keywords

CHEMOTHERAPY; STABILIZERS (AGENTS); STANDARDS;

CLINICAL TESTING; DIRECT ACCESS; ELSEVIER (CO); IN ORDER; PERITONEAL CAVITIES; PRECLINICAL DEVELOPMENT; UNITED STATES;

HEALTH;

ALEMTUZUMAB; ANTIBODY; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; APOLIZUMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; EPRATUZUMAB; GALIXIMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G ANTIBODY I 125; IMMUNOGLOBULIN G ANTIBODY I 131; LABETUZUMAB; LINTUZUMAB; MONOCLONAL ANTIBODY TENASCIN I 131; MUC1 ANTIBODY Y 90; RITUXIMAB; TOSITUMOMAB; TRASTUZUMAB; ZANOLIMUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; BEAM THERAPY; BLOOD TOXICITY; BRAIN CANCER; BYSTANDER EFFECT; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GLIOBLASTOMA; HUMAN; ISOTOPE LABELING; LEUKEMIA CELL; LIVER TOXICITY; LYMPHOCYTOPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIATION NECROSIS; REVIEW; STEREOTACTIC RADIOSURGERY;

ANIMALS; ANTIBODIES; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; LEUKEMIA; LYMPHOMA; NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 46849110142     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.04.011     Document Type: Review

References (242)

1. Fidler I.J. Origin of cancer metastases and its implications for therapy. Isr. J. Med. Sci. 24 (1988) 456-463
2. Langley R.R., and Fidler I.J. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev. 28 (2007) 297-321
3. Fisher E.R., and Fisher B. Recent observations on concepts of metastasis. Arch. Pathol. 83 (1967) 321-324
4. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
5. Herlyn D., and Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 4761-4765
6. Herlyn D.M., Steplewski Z., Herlyn M.F., and Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 40 (1980) 717-721
7. Herlyn D., Herlyn M., Steplewski Z., and Koprowski H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur. J. Immunol. 9 (1979) 657-659
8. Hellstrom I., Brankovan V., and Hellstrom K.E. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 1499-1502
9. Sears H.F., Herlyn D., Steplewski Z., and Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. 45 (1985) 5910-5913
10. Lobuglio A.F., Saleh M., Peterson L., Wheeler R., Carrano R., Huster W., and Khazaeli M.B. Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma 5 Suppl 1 (1986) S117-S123
11. Frodin J.E., Biberfeld P., Christensson B., Philstedt P., Sundelius S., Sylven M., Wahren B., Koprowski H., and Mellstedt H. Treatment of patients with metastasizing colo-rectal carcinoma with mouse monoclonal antibodies (Moab 17-1A): a progress report. Hybridoma 5 Suppl 1 (1986) S151-S161
12. Miller R.A., and Levy R. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2 (1981) 226-230
13. Goodman G.E., Beaumier P., Hellstrom I., Fernyhough B., and Hellstrom K.E. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J. Clin. Oncol. 3 (1985) 340-352
14. Dillman R.O., Shawler D.L., Dillman J.B., and Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J. Clin. Oncol. 2 (1984) 881-891
15. Ritz J., and Schlossman S.F. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood 59 (1982) 1-11
16. Trowbridge I.S., and Domingo D.L. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature 294 (1981) 171-173
17. Masui H., Kawamoto T., Sato J.D., Wolf B., Sato G., and Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44 (1984) 1002-1007
18. Cilley J.C., Barfi K., Benson III A.B., and Mulcahy M.F. Bevacizumab in the treatment of colorectal cancer. Expert Opin. Biol. Ther. 7 (2007) 739-749
19. Giantonio B.J., Catalano P.J., Meropol N.J., O'dwyer P.J., Mitchell E.P., Alberts S.R., Schwartz M.A., and Benson III A.B. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25 (2007) 1539-1544
20. Panares R.L., and Garcia A.A. Bevacizumab in the management of solid tumors. Expert Rev. Anticancer Ther. 7 (2007) 433-445
21. Maloney D.G. Preclinical and phase I and II trials of rituximab. Semin. Oncol. 26 (1999) 74-78
22. Valabrega G., Montemurro F., and Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 18 (2007) 977-984
23. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 26 (2007) 3629-3636
24. Grillo-Lopez A.J., Dallaire B.K., Mcclure A., Weaver R., Varns C., Wei A., Allen R., Lee D., Shen D., Leonard J., Multani P., and White C.A. Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma. Curr. Pharm. Biotechnol. 2 (2001) 301-311
25. Coiffier B. Treatment of non-Hodgkin's lymphoma: a look over the past decade. Clin. Lymphoma Myeloma 7 Suppl 1 (2006) S7-S13
26. Hainsworth J.D., Litchy S., Shaffer D.W., Lackey V.L., Grimaldi M., and Greco F.A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23 (2005) 1088-1095
27. Collins-Burow B., and Santos E.S. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Expert Rev. Anticancer Ther. 7 (2007) 257-273
28. Thieblemont C., and Coiffier B. Lymphoma in older patients. J. Clin. Oncol. 25 (2007) 1916-1923
29. Marcus R. Use of rituximab in patients with follicular lymphoma. Clin. Oncol. (R. Coll. Radiol.) 19 (2007) 38-49
30. Marcus R., and Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur. J. Haematol., Suppl (2007) 5-14
31. Presta L.G. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Deliv. Rev. 58 (2006) 640-656
32. Daugherty A.L., and Mrsny R.J. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Deliv. Rev. 58 (2006) 686-706
33. Helguera G., and Penichet M.L. Antibody-cytokine fusion proteins for the therapy of cancer. Methods Mol. Med. 109 (2005) 347-374
34. Pastan I., Hassan R., Fitzgerald D.J., and Kreitman R.J. Immunotoxin treatment of cancer. Annu. Rev. Med. 58 (2007) 221-237
35. Kiewe P., Hasmuller S., Kahlert S., Heinrigs M., Rack B., Marme A., Korfel A., Jager M., Lindhofer H., Sommer H., Thiel E., and Untch M. Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin. Cancer Res. 12 (2006) 3085-3091
36. Brischwein K., Schlereth B., Guller B., Steiger C., Wolf A., Lutterbuese R., Offner S., Locher M., Urbig T., Raum T., Kleindienst P., Wimberger P., Kimmig R., Fichtner I., Kufer P., Hofmeister R., Da Silva A.J., and Baeuerle P.A. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol. Immunol. 43 (2006) 1129-1143
37. Manzke O., Tesch H., Borchmann P., Wolf J., Lackner K., Gossmann A., Diehl V., and Bohlen H. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation. Int. J. Cancer 91 (2001) 508-515
38. De Gast G.C., Van Houten A.A., Haagen I.A., Klein S., De Weger R.A., Van Dijk A., Phillips J., Clark M., and Bast B.J. Clinical experience with CD3 × CD19 bispecific antibodies in patients with B cell malignancies. J. Hematother. 4 (1995) 433-437
39. Rossi E.A., Goldenberg D.M., Cardillo T.M., Mcbride W.J., Sharkey R.M., and Chang C.H. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 6841-6846
40. Sharkey R.M., and Goldenberg D.M. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J. Clin. 56 (2006) 226-243
41. Goldenberg D.M., and Sharkey R.M. Novel radiolabeled antibody conjugates. Oncogene 26 (2007) 3734-3744
42. Beckman R.A., Weiner L.M., and Davis H.M. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109 (2007) 170-179
43. Feldman E.J., Brandwein J., Stone R., Kalaycio M., Moore J., O'connor J., Wedel N., Roboz G.J., Miller C., Chopra R., Jurcic J.C., Brown R., Ehmann W.C., Schulman P., Frankel S.R., De Angelo D., and Scheinberg D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol. 23 (2005) 4110-4116
44. Lambert J.M. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol. 5 (2005) 543-549
45. Davis T.A., Kaminski M.S., Leonard J.P., Hsu F.J., Wilkinson M., Zelenetz A., Wahl R.L., Kroll S., Coleman M., Goris M., Levy R., and Knox S.J. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin. Cancer Res. 10 (2004) 7792-7798
46. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R., Pohlman B.L., Bartlett N.L., Wiseman G.A., Padre N., Grillo-Lopez A.J., Multani P., and White C.A. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20 (2002) 2453-2463
47. Vitetta E.S. Immunotoxins and vascular leak syndrome. Cancer J. 6 Suppl 3 (2000) S218-S224
48. Cattel L., Delprino L., Brusa P., Dosio F., Comoglio P.M., and Prat M. Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines. Cancer Immunol. Immunother. 27 (1988) 233-240
49. Brusa P., Dosio F., Pietribiasi F., Delprino L., Feraiorni P., Mariani M., Bussolati G., and Cattel L. Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice. Cancer Immunol. Immunother. 35 (1992) 373-380
50. Baluna R., Coleman E., Jones C., Ghetie V., and Vitetta E.S. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp. Cell Res. 258 (2000) 417-424
51. Smallshaw J.E., Ghetie V., Rizo J., Fulmer J.R., Trahan L.L., Ghetie M.A., and Vitetta E.S. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat. Biotechnol. 21 (2003) 387-391
52. Messmer D., and Kipps T.J. Treatment of solid tumors with immunotoxins. Breast Cancer Res. 7 (2005) 184-186
53. Kreitman R.J. Toxin-labeled monoclonal antibodies. Curr. Pharm. Biotechnol. 2 (2001) 313-325
54. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24 (2002) 1720-1740
55. Newton D.L., and Ryback S.M. Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA. Expert Opin. Biol. Ther. 1 (2001) 995-1003
56. Hellstrom I., Garrigues H.J., Garrigues U., and Hellstrom K.E. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res. 50 (1990) 2183-2190
57. Tolcher A.W., Sugarman S., Gelmon K.A., Cohen R., Saleh M., Isaacs C., Young L., Healey D., Onetto N., and Slichenmyer W. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 17 (1999) 478-484
58. Ravjvanshi P., Shulman H.M., Sievers E.L., and Mcdonald G.B. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 99 (2002) 2310-2314
59. Sharkey R.M., and Goldenberg D.M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46 Suppl 1 (2005) 115S-127S
60. Goldenberg D.M., Sharkey R.M., Paganelli G., Barbet J., and Chatal J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24 (2006) 823-834
61. Hansen H.J., Ong G.L., Diril H., Valdez A., Roche P.A., Griffiths G.L., Goldenberg D.M., and Mattes M.J. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem. J. 320 Pt 1 (1996) 293-300
62. Chang C.H., Sapra P., Vanama S.S., Hansen H.J., Horak I.D., and Goldenberg D.M. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 106 (2005) 4308-4314
63. Sapra P., Stein R., Pickett J., Qu Z., Govindan S.V., Cardillo T.M., Hansen H.J., Horak I.D., Griffiths G.L., and Goldenberg D.M. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin. Cancer Res. 11 (2005) 5257-5264
64. Michel R.B., Rosario A.V., Andrews P.M., Goldenberg D.M., and Mattes M.J. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. Clin. Cancer Res. 11 (2005) 777-786
65. Griffiths G.L., Mattes M.J., Stein R., Govindan S.V., Horak I.D., Hansen H.J., and Goldenberg D.M. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin. Cancer Res. 9 (2003) 6567-6571
66. Ong G.L., Elsamra S.E., Goldenberg D.M., and Mattes M.J. Single-cell cytotoxicity with radiolabeled antibodies. Clin. Cancer Res. 7 (2001) 192-201
67. Starlets D., Gore Y., Binsky I., Haran M., Harpaz N., Shvidel L., Becker-Herman S., Berrebi A., and Shachar I. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107 (2006) 4807-4816
68. Stein R., Qu Z., Cardillo T.M., Chen S., Rosario A., Horak I.D., Hansen H.J., and Goldenberg D.M. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 104 (2004) 3705-3711
69. Ghose T., and Blair A.H. Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects. J. Natl. Cancer Inst. 61 (1978) 657-676
70. Ghose T., and Blair A.H. The design of cytotoxic-agent-antibody conjugates. Crit. Rev. Ther. Drug Carr. Syst. 3 (1987) 263-359
71. Kreitman R.J., and Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res. 58 (1998) 968-975
72. Schrama D., Reisfeld R.A., and Becker J.C. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 5 (2006) 147-159
73. Wu A.M., and Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23 (2005) 1137-1146
74. Arnon R. Site-directed tumor chemotherapy. Compr. Ther. 4 (1978) 68-73
75. Jedema I., Barge R.M., Van Der Velden V.H., Nijmeijer B.A., Van Dongen J.J., Willemze R., and Falkenburg J.H. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18 (2004) 316-325
76. Dubowchik G.M., Firestone R.A., Padilla L., Willner D., Hofstead S.J., Mosure K., Knipe J.O., Lasch S.J., and Trail P.A. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 13 (2002) 855-869
77. Suzawa T., Nagamura S., Saito H., Ohta S., Hanai N., Kanazawa J., Okabe M., and Yamasaki M. Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker. J. Control. Release 79 (2002) 229-242
78. Mueller B.M., Wrasidlo W.A., and Reisfeld R.A. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. Bioconjug. Chem. 1 (1990) 325-330
79. Govindan S.V., Griffiths G.L., Hansen H.J., Horak I.D., and Goldenberg D.M. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. Technol. Cancer Res. Treat. 4 (2005) 375-391
80. Kovtun Y.V., Audette C.A., Ye Y., Xie H., Ruberti M.F., Phinney S.J., Leece B.A., Chittenden T., Blattler W.A., and Goldmacher V.S. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66 (2006) 3214-3221
81. Denny W.A. Tumor-activated prodrugs-a new approach to cancer therapy. Cancer Investig. 22 (2004) 604-619
82. Chan S.Y., Gordon A.N., Coleman R.E., Hall J.B., Berger M.S., Sherman M.L., Eten C.B., and Finkler N.J. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol. Immunother. 52 (2003) 243-248
83. Mayer A., Francis R.J., Sharma S.K., Tolner B., Springer C.J., Martin J., Boxer G.M., Bell J., Green A.J., Hartley J.A., Cruickshank C., Wren J., Chester K.A., and Begent R.H. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin. Cancer Res. 12 (2006) 6509-6516
84. Sharma S.K., Bagshawe K.D., and Begent R.H. Advances in antibody-directed enzyme prodrug therapy. Curr. Opin. Investig. Drugs 6 (2005) 611-615
85. Schwulst S.J., Davis C.G., Coopersmith C.M., and Hotchkiss R.S. Adoptive transfer of dying cells causes bystander-induced apoptosis. Biochem. Biophys. Res. Commun. 353 (2007) 780-785
86. Cairns R., Papandreou I., and Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res. 4 (2006) 61-70
87. Goldenberg D.M., Preston D.F., Primus F.J., and Hansen H.J. Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res. 34 (1974) 1-9
88. Duran-Reynals F. Studies on the localization of dyes and foreign proteins in normal and malignant tissues. Am. J. Cancer 35 (1939) 98-107
89. Fujimori K., Covell D.G., Fletcher J.E., and Weinstein J.N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med. 31 (1990) 1191-1198
90. Baxter L.T., Zhu H., Mackensen D.G., and Jain R.K. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 54 (1994) 1517-1528
91. Adams G.P., Schier R., Mccall A.M., Simmons H.H., Horak E.M., Alpaugh R.K., Marks J.D., and Weiner L.M. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61 (2001) 4750-4755
92. Blumenthal R.D., Fand I., Sharkey R.M., Boerman O.C., Kashi R., and Goldenberg D.M. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol. Immunother. 33 (1991) 351-358
93. Graff C.P., and Wittrup K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63 (2003) 1288-1296
94. Van Osdol W., Fujimori K., and Weinstein J.N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Res. 51 (1991) 4776-4784
95. Baxter L.T., and Jain R.K. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc. Res. 41 (1991) 5-23
96. Sato N., Saga T., Sakahara H., Yao Z., Nakamoto Y., Zhang M., Kuroki M., Matsuoka Y., Iida Y., and Konishi J. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse. J. Nucl. Med. 40 (1999) 685-692
97. Boerman O.C., Sharkey R.M., Wong G.Y., Blumenthal R.D., Aninipot R.L., and Goldenberg D.M. Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor. Cancer Immunol. Immunother. 35 (1992) 127-134
98. Knox S.J., Goris M.L., Trisler K., Negrin R., Davis T., Liles T.M., Grillo-Lopez A., Chinn P., Varns C., Ning S.C., Fowler S., Deb N., Becker M., Marquez C., and Levy R. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2 (1996) 457-470
99. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329 (1993) 459-465
100. Khawli L.A., Biela B., Hu P., and Epstein A.L. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybrid Hybridomics 22 (2003) 1-9
101. Daugherty A.L., and Mrsny R.J. Emerging technologies that overcome biological barriers for therapeutic protein delivery. Expert Opin. Biol. Ther. 3 (2003) 1071-1081
102. Ferguson S., and Lesniak M.S. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr. Drug Deliv. 4 (2007) 169-180
103. Guo J., Zhu J., Sheng X., Wang X., Qu L., Han Y., Liu Y., Zhang H., Huo L., Zhang S., Lin B., and Yang Z. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int. J. Cancer 120 (2007) 2418-2425
104. Vukelja S.J., Anthony S.P., Arseneau J.C., Berman B.S., Cunningham C.C., Nemunaitis J.J., Samlowski W.E., and Fowers K.D. Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anticancer Drugs 18 (2007) 283-289
105. Seror O., N'kontchou G., Tin Tin Htar M., Durand-Zaleski I., Trinchet J.C., Sellier N., and Beaugrand M. Ethanol versus radiofrequency ablation for the treatment of small hepatocellular carcinoma in patients with cirrhosis: a retrospective study of efficacy and cost. Gastroenterol. Clin. Biol. 30 (2006) 1265-1273
106. Matthes K., Mino-Kenudson M., Sahani D.V., Holalkere N., Fowers K.D., Rathi R., and Brugge W.R. EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas (with video). Gastrointest. Endosc. 65 (2007) 448-453
107. Gonzalez R., Hutchins L., Nemunaitis J., Atkins M., and Schwarzenberger P.O. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res. 16 (2006) 521-526
108. Kerl K., Prins C., Saurat J.H., and French L.E. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br. J. Dermatol. 155 (2006) 1197-1200
109. Ter Horst M., Verwijnen S.M., Brouwer E., Hoeben R.C., De Jong M., De Leeuw B.H., and Sillevis Smitt P.A. Locoregional delivery of adenoviral vectors. J. Nucl. Med. 47 (2006) 1483-1489
110. Lorenz M., and Muller H.H. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J. Clin. Oncol. 18 (2000) 243-254
111. Ducreux M., Ychou M., Laplanche A., Gamelin E., Lasser P., Husseini F., Quenet F., Viret F., Jacob J.H., Boige V., Elias D., Delperro J.R., and Luboinski M. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J. Clin. Oncol. 23 (2005) 4881-4887
112. Kemeny N., Daly J., Reichman B., Geller N., Botet J., and Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann. Intern. Med. 107 (1987) 459-465
113. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., and Kaveri S.V. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat. Clin. Pract. Rheumatol. 3 (2007) 262-272
114. Kaczmarek I., Deutsch M.A., Sadoni S., Brenner P., Schmauss D., Daebritz S.H., Weiss M., Meiser B.M., and Reichart B. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J. Heart Lung Transplant. 26 (2007) 511-515
115. Sperr W.R., Lechner K., and Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 92 (2007) 66-71
116. Eisenberg R. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Endocr. Metab. Immune Disord. Drug. Targets 6 (2006) 345-350
117. Srock S., Schriever F., Neubauer A., Herold M., and Huhn D. Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy. Leuk. Lymphoma 48 (2007) 905-911
118. Kay N.E., Geyer S.M., Call T.G., Shanafelt T.D., Zent C.S., Jelinek D.F., Tschumper R., Bone N.D., Dewald G.W., Lin T.S., Heerema N.A., Smith L., Grever M.R., and Byrd J.C. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109 (2007) 405-411
119. Cheson B.D. Monoclonal antibody therapy for B-cell malignancies. Semin. Oncol. 33 (2006) S2-S14
120. Czuczman M.S., Thall A., Witzig T.E., Vose J.M., Younes A., Emmanouilides C., Miller T.P., Moore J.O., Leonard J.P., Gordon L.I., Sweetenham J., Alkuzweny B., Finucane D.M., and Leigh B.R. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J. Clin. Oncol. 23 (2005) 4390-4398
121. Goldenberg D.M. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev. Anticancer Ther. 6 (2006) 1341-1353
122. Leonard J., Friedberg J., Younes A., Fisher D., Gordon L., Moore J., zCzuczman M., Miller T., Stiff P., Cheson B., Forero-Torres A., Chieffo N., Mckinney B., Finucane D., and Molina A. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann. Oncol. 18 (2007) 1216-1223
123. Leonard J.P., Coleman M., Ketas J., Ashe M., Fiore J.M., Furman R.R., Niesvizky R., Shore T., Chadburn A., Horne H., Kovacs J., Ding C.L., Wegener W.A., Horak I.D., and Goldenberg D.M. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 23 (2005) 5044-5051
124. Strauss S.J., Morschhauser F., Rech J., Repp R., Solal-Celigny P., Zinzani P.L., Engert A., Coiffier B., Hoelzer D.F., Wegener W.A., Teoh N.K., Goldenberg D.M., and Lister T.A. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 24 (2006) 3880-3886
125. Rech J., Repp R., Rech D., Stockmeyer B., Dechant M., Niedobitek G., Gramatzki M., and Valerius T. A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. LeukLymphoma 47 (2006) 2147-2154
126. Abutalib S.A., and Tallman M.S. Monoclonal antibodies for the treatment of acute myeloid leukemia. Curr. Pharm. Biotechnol. 7 (2006) 343-369
127. Sievers E.L. Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Cancer Chemother. Pharmacol. 46 (2000) S18-S22 Suppl
128. Scheinberg D.A., Jurcic J.G., and Maslak P. Antibody-drug conjugates in acute myeloid leukemia. Nat. Clin. Pract. Oncol. 3 (2006) 238-239
129. Zenz T., Glatting G., Schlenk R.F., Buchmann I., Dohner H., Reske S.N., and Bunjes D. Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study. Haematologica 91 (2006) 285-286
130. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk. Lymphoma 43 (2002) 2125-2131
131. Glatting G., Muller M., Koop B., Hohl K., Friesen C., Neumaier B., Berrie E., Bird P., Hale G., Blumstein N.M., Waldmann H., Bunjes D., and Reske S.N. Anti-CD45 monoclonal antibody YAML568: a promising radioimmunoconjugate for targeted therapy of acute leukemia. J. Nucl. Med. 47 (2006) 1335-1341
132. Bethge W.A., Wilbur D.S., and Sandmaier B.M. Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation. Leuk. Lymphoma 47 (2006) 1205-1214
133. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107 (2006) 2184-2191
134. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94 (1999) 1237-1247
135. Waldmann T.A. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 26 (2007) 3699-3703
136. Waldmann T.A. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol. 27 (2007) 1-18
137. Kreitman R.J., Wilson W.H., White J.D., Stetler-Stevenson M., Jaffe E.S., Giardina S., Waldmann T.A., and Pastan I. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18 (2000) 1622-1636
138. Kim Y.H., Duvic M., Obitz E., Gniadecki R., Iversen L., Osterborg A., Whittaker S., Illidge T.M., Schwarz T., Kaufmann R., Cooper K., Knudsen K.M., Lisby S., Baadsgaard O., and Knox S.J. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109 (2007) 4655-4662
139. Maslak P.G., Jurcic J.G., and Scheinberg D.A. Monoclonal antibody therapy of APL. Curr. Top. Microbiol. Immunol. 313 (2007) 205-219
140. Scheinberg D.A., Lovett D., Divgi C.R., Graham M.C., Berman E., Pentlow K., Feirt N., Finn R.D., Clarkson B.D., Gee T.S., et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J. Clin. Oncol. 9 (1991) 478-490
141. Van Der Velden V.H., Te Marvelde J.G., Hoogeveen P.G., Bernstein I.D., Houtsmuller A.B., Berger M.S., and Van Dongen J.J. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97 (2001) 3197-3204
142. Mulford D.A., Scheinberg D.A., and Jurcic J.G. The promise of targeted {alpha}-particle therapy. J. Nucl. Med. 46 Suppl 1 (2005) 199S-204S
143. Jazirehi A.R., Vega M.I., and Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 67 (2007) 1270-1281
144. Czuczman M.S. Combination chemotherapy and rituximab. Anticancer Drugs 12 Suppl 2 (2001) S15-S19
145. Del Poeta G., Ilaria Del Principe M., Buccisano F., Maurillo L., Niscola P., Venditti A., and Amadori S. Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia. Expert Rev. Anticancer Ther. 6 (2006) 1787-1800
146. Scott A.M., Wiseman G., Welt S., Adjei A., Lee F.T., Hopkins W., Divgi C.R., Hanson L.H., Mitchell P., Gansen D.N., Larson S.M., Ingle J.N., Hoffman E.W., Tanswell P., Ritter G., Cohen L.S., Bette P., Arvay L., Amelsberg A., Vlock D., Rettig W.J., and Old L.J. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9 (2003) 1639-1647
147. Pantelias A., Pagel J.M., Hedin N., Saganic L., Wilbur S., Hamlin D.K., Wilbur D.S., Lin Y., Stone D., Axworthy D., Gopal A.K., and Press O.W. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood 109 (2007) 4980-4987
148. Raderer M., Jager G., Brugger S., Puspok A., Fiebiger W., Drach J., Wotherspoon A., and Chott A. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 65 (2003) 306-310
149. Rubenstein J.L., Fridlyand J., Abrey L., Shen A., Karch J., Wang E., Issa S., Damon L., Prados M., Mcdermott M., O'Brien J., Haqq C., and Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol. 25 (2007) 1350-1356
150. Dedrick R.L., Myers C.E., Bungay P.M., and Devita Jr. V.T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62 (1978) 1-11
151. Choi J., Credit K., Henderson K., Deverkadra R., He Z., Wiig H., Vanpelt H., and Flessner M.F. Intraperitoneal immunotherapy for metastatic ovarian carcinoma: resistance of intratumoral collagen to antibody penetration. Clin. Cancer Res. 12 (2006) 1906-1912
152. Davies Cde L., Berk D.A., Pluen A., and Jain R.K. Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br. J. Cancer 86 (2002) 1639-1644
153. Wenning L.A., and Murphy R.M. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol. Bioeng. 62 (1999) 562-575
154. Hjelstuen M.H., Rasch-Halvorsen K., Bruland O., and De L.D.C. Uptake, penetration, and binding of monoclonal antibodies with increasing affinity in human osteosarcoma multicell spheroids. Anticancer Res. 18 (1998) 3153-3161
155. Colcher D., Esteban J., Carrasquillo J.A., Sugarbaker P., Reynolds J.C., Bryant G., Larson S.M., and Schlom J. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res. 47 (1987) 4218-4224
156. Van Zanten-Przybysz I., Molthoff C.F., Roos J.C., Verheijen R.H., Van Hof A., Buist M.R., Prinssen H.M., Den Hollander W., and Kenemans P. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int. J. Cancer 92 (2001) 106-114
157. 32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21 (2003) 2849-2855
158. Young R.C., Brady M.F., Nieberg R.K., Long H.J., Mayer A.R., Lentz S.S., Hurteau J., and Alberts D.S. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin-a gynecologic oncology group study. J. Clin. Oncol. 21 (2003) 4350-4355
159. 90Y-biotin?. Gynecol. Oncol. 93 (2004) 691-698
160. 177Lu-CC49: a phase I/II study. Gynecol. Oncol. 65 (1997) 94-101
161. Mahe M.A., Fumoleau P., Fabbro M., Guastalla J.P., Faurous P., Chauvot P., Chetanoud L., Classe J.M., Rouanet P., and Chatal J.F. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin. Cancer Res. 5 (1999) 3249s-3253s
162. Oei A.L., Verheijen R.H., Seiden M.V., Benigno B.B., Lopes A., Soper J.T., Epenetos A.A., and Massuger L.F. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int. J. Cancer 120 (2007) 2710-2714
163. 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. 8 (2002) 2806-2811
164. Juweid M., Sharkey R.M., Alavi A., Swayne L.C., Herskovic T., Hanley D., Rubin A.D., Pereira M., and Goldenberg D.M. Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody. J. Nucl. Med. 38 (1997) 257-260
165. Juweid M., Swayne L.C., Sharkey R.M., Dunn R., Rubin A.D., Herskovic T., and Goldenberg D.M. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies. Gynecol. Oncol. 67 (1997) 259-271
166. Verheijen R.H., Massuger L.F., Benigno B.B., Epenetos A.A., Lopes A., Soper J.T., Markowska J., Vyzula R., Jobling T., Stamp G., Spiegel G., Thurston D., Falke T., Lambert J., and Seiden M.V. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol. 24 (2006) 571-578
167. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., and Burger R.A. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
168. 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J. Nucl. Med. 45 (2004) 1224-1232
169. Koppe M.J., Hendriks T., Boerman O.C., Oyen W.J., and Bleichrodt R.P. adioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J. Nucl. Med. 47 (2006) 1867-1874
170. Aarts F., Koppe M.J., Hendriks T., Van Eerd J.E., Oyen W.J., Boerman O.C., and Bleichrodt R.P. Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin. Ann. Surg. Oncol. 14 (2007) 533-540
171. 211At-labeled monoclonal antibody MX35. J. Nucl. Med. 46 (2005) 1907-1915
172. Milenic D.E., Garmestani K., Brady E.D., Albert P.S., Abdulla A., Flynn J., and Brechbiel M.W. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin. Cancer Res. 13 (2007) 1926-1935
173. Janssen M.L., Pels W., Massuger L.F., Oyen W.J., Boonstra H., Corstens F.H., and Boerman O.C. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide. Int. J. Gynecol. Cancer 13 (2003) 607-613
174. 90Y-biotin radioimmunotherapy and temozolomide. Q. J. Nucl. Med. Mol. Imaging 48 (2004) 220-228
175. 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother. Radiopharm. 16 (2001) 227-235
176. Reardon D.A., Zalutsky M.R., and Bigner D.D. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev. Anticancer Ther. 7 (2007) 675-687
177. Rao R.D., Brown P.D., and Buckner J.C. Innovation in the management of brain metastases. Oncology 21 (2007) 473-481
178. Muldoon L.L., Soussain C., Jahnke K., Johanson C., Siegal T., Smith Q.R., Hall W.A., Hynynen K., Senter P.D., Peereboom D.M., and Neuwelt E.A. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 25 (2007) 2295-2305
179. Penas-Prado M., and Gilbert M.R. Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev. Anticancer Ther. 7 (2007) 641-661
180. Yau T., Swanton C., Chua S., Sue A., Walsh G., Rostom A., Johnston S.R., O'Brien M.E., and Smith I.E. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 45 (2006) 196-201
181. Gerber D.E., and Laterra J. Emerging monoclonal antibody therapies for malignant gliomas. Expert Opin. Investig. Drugs 16 (2007) 477-494
182. McLendon R.E., Akabani G., Friedman H.S., Reardon D.A., Cleveland L., Cokgor I., Herndon II J.E., Wikstrand C., Boulton S.T., Friedman A.H., Bigner D.D., and Zalutsky M.R. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl. Med. Biol. 34 (2007) 405-413
183. 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20 (2002) 1389-1397
184. Reardon D.A., Akabani G., Coleman R.E., Friedman A.H., Friedman H.S., Herndon II J.E., McLendon R.E., Pegram C.N., Provenzale J.M., Quinn J.A., Rich J.N., Vredenburgh J.J., Desjardins A., Gururangan S., Badruddoja M., Dowell J.M., Wong T.Z., Zhao X.G., Zalutsky M.R., and Bigner D.D. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J. Clin. Oncol. 24 (2006) 115-122
185. 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J. Nucl. Med. 47 (2006) 912-918
186. 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. 55 (1995) 5952s-5956s
187. 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J. Nucl. Med. 46 (2005) 1042-1051
188. Grana C., Chinol M., Robertson C., Mazzetta C., Bartolomei M., De Cicco C., Fiorenza M., Gatti M., Caliceti P., and Paganelli G. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer 86 (2002) 207-212
189. Paganelli G., Grana C., Chinol M., Cremonesi M., De Cicco C., De Braud F., Robertson C., Zurrida S., Casadio C., Zoboli S., Siccardi A.G., and Veronesi U. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med. 26 (1999) 348-357
190. Sampson J.H., Akabani G., Friedman A.H., Bigner D., Kunwar S., Berger M.S., and Bankiewicz K.S. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg. Focus 20 (2006) E14
191. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin. Cancer Res. 2 (1996) 963-972
192. Vitaz T.W., Warnke P.C., Tabar V., and Gutin P.H. Brachytherapy for brain tumors. J. Neuro-oncol. 73 (2005) 71-86
193. Gabayan A.J., Green S.B., Sanan A., Jenrette J., Schultz C., Papagikos M., Tatter S.P., Patel A., Amin P., Lustig R., Bastin K.T., Watson G., Burri S., and Stea B. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 58 (2006) 701-709 discussion 701-709
194. Welsh J., Sanan A., Gabayan A.J., Green S.B., Lustig R., Burri S., Kwong E., and Stea B. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int. J. Radiat. Oncol. Biol. Phys. 68 (2007) 159-165
195. Geschwind J.F., Salem R., Carr B.I., Soulen M.C., Thurston K.G., Goin K.A., Van Buskirk M., Roberts C.A., and Goin J.E. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 (2004) S194-S205
196. 32P) brachytherapy delivery device-a first-in-man study. Int. J. Radiat. Oncol. Biol. Phys. 67 (2007) 786-792
197. Order S.E., Siegel J.A., Lustig R.A., Principato R., Zeiger L.S., Johnson E., Zhang H., Lang P., Pilchik N.B., Metz J., et al. A new method for delivering radioactive cytotoxic agents in solid cancers. Int. J. Radiat. Oncol. Biol. Phys. 30 (1994) 715-720
198. 32P. Int. J. Radiat. Oncol. Biol. Phys. 39 (1997) 481-487
199. 32P. Ann. Acad. Med. Singap. 25 (1996) 347-351
200. 32P radioisotope therapy for recurrent pilocytic astrocytoma. Brachytherapy 4 (2005) 171-173
201. 32P radiation in the treatment of craniopharyngiomas. J. Neuro-oncol. 56 (2002) 69-78
202. Taasan V., Shapiro B., Taren J.A., Beierwaltes W.H., Mckeever P., Wahl R.L., Carey J.E., Petry N., and Mallette S. Phosphorus-32 therapy of cystic Grade IV astrocytomas: technique and preliminary application. J. Nucl. Med. 26 (1985) 1335-1338
203. Hasegawa T., Kondziolka D., Hadjipanayis C.G., and Lunsford L.D. Management of cystic craniopharyngiomas with phosphorus-32 intracavitary irradiation. Neurosurgery 54 (2004) 813-820 discussion 820-812
204. Szeifert G.T., Julow J., Slowik F., Balint K., Lanyi F., and Pasztor E. Pathological changes in cystic craniopharyngiomas following intracavital 90yttrium treatment. Acta Neurochir. (Wien) 102 (1990) 14-18
205. Szeifert G.T., Balint K., Sipos L., Sarker M.H., Czirjak S., and Julow J. Pathological findings in cystic craniopharyngiomas after stereotactic intracavitary irradiation with yttrium-90 isotope. Prog. Neurol. Surg. 20 (2007) 297-302
206. 131I-labeled anti-tenascin monoclonal antibody 81C6. Cancer Res. 48 (1988) 2904-2910
207. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 49 (1989) 2807-2813
208. 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J. Nucl. Med. 40 (1999) 631-638
209. Selker R.G., Mendelow H., Walker M., Sheptak P.E., and Phillips J.G. Pathological correlation of CT ring in recurrent, previously treated gliomas. Surg. Neurol. 17 (1982) 251-254
210. 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 972-975
211. Gonzalez J., Kumar A.J., Conrad C.A., and Levin V.A. Effect of bevacizumab on radiation necrosis of the brain. Int. J. Radiat. Oncol. Biol. Phys. 67 (2007) 323-326
212. Belda-Iniesta C., Carpeno Jde C., Saenz E.C., Gutierrez M., Perona R., and Baron M.G. Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol. Ther. 5 (2006) 912-914
213. Combs S.E., Heeger S., Haselmann R., Edler L., Debus J., and Schulz-Ertner D. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-phase I/II trial: study protocol. BMC Cancer 6 (2006) 133
214. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., and Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
215. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., Mcfadden E., Dolci M.S., and Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1659-1672
216. De Gramont A., Tournigand C., Andre T., Larsen A.K., and Louvet C. Adjuvant therapy for stage II and III colorectal cancer. Semin. Oncol. 34 (2007) S37-S40
217. Zhang W., Gordon M., and Lenz H.J. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann. Med. 38 (2006) 545-551
218. Caprioni F., and Fornarini G. Bevacizumab in the treatment of metastatic colorectal cancer. Future Oncol. 3 (2007) 141-148
219. Press O.W., Unger J.M., Braziel R.M., Maloney D.G., Miller T.P., Leblanc M., and Fisher R.I. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J. Clin. Oncol. 24 (2006) 4143-4149
220. Kaminski M.S., Radford J.A., Gregory S.A., Leonard J.P., Knox S.J., Kroll S., and Wahl R.L. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J. Clin. Oncol. 23 (2005) 7985-7993
221. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352 (2005) 441-449
222. 131 tositumomab. Oncogene 26 (2007) 3614-3628
223. Shimoni A., Zwas S.T., Oksman Y., Hardan I., Shem-Tov N., Yerushalmi R., Avigdor A., Ben-Bassat I., and Nagler A. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp. Hematol. 35 (2007) 534-540
224. Emmanouilides C., Witzig T.E., Gordon L.I., Vo K., Wiseman G.A., Flinn I.W., Darif M., Schilder R.J., and Molina A. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk. Lymphoma 47 (2006) 629-636
225. 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res. 47 (1987) 5672-5677
226. Boerman O.C., Sharkey R.M., Blumenthal R.D., Aninipot R.L., and Goldenberg D.M. The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors. Int. J. Cancer 51 (1992) 470-475
227. 131I-labeled monoclonal antibodies. Cancer Res. 52 (1992) 6036-6044
228. Sharkey R.M., Weadock K.S., Natale A., Haywood L., Aninipot R., Blumenthal R.D., and Goldenberg D.M. Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J. Natl. Cancer Inst. 83 (1991) 627-632
229. 131I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann. Surg. Oncol. 14 (2007) 2577-2590
230. 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J. Clin. Oncol. 23 (2005) 6763-6770
231. Chatal J.F., Campion L., Kraeber-Bodere F., Bardet S., Vuillez J.P., Charbonnel B., Rohmer V., Chang C.H., Sharkey R.M., Goldenberg D.M., and Barbet J. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J. Clin. Oncol. 24 (2006) 1705-1711
232. Clarke K., Lee F.T., Brechbiel M.W., Smyth F.E., Old L.J., and Scott A.M. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin. Cancer Res. 6 (2000) 3621-3628
233. DeNardo S.J., Kroger L.A., Lamborn K.R., Miers L.A., O'Donnell R.T., Kukis D.L., Richman C.M., and DeNardo G.L. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer 80 (1997) 2583-2590
234. 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother. Radiopharm. 13 (1998) 351-361
235. O'Donnell R.T., DeNardo S.J., Miers L.A., Lamborn K.R., Kukis D.L., DeNardo G.L., and Meyers F.J. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate 50 (2002) 27-37
236. Supiot S., Gouard S., Charrier J., Apostolidis C., Chatal J.F., Barbet J., Davodeau F., and Cherel M. Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin. Cancer Res. 11 (2005) 7047s-7052s
237. 131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res. 57 (1997) 2181-2186
238. 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration. Cancer Biother. Radiopharm. 20 (2005) 467-478
239. 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin. Cancer Res. 9 (2003) 5842-5852
240. Richman C.M., DeNardo S.J., O'Donnell R.T., Yuan A., Shen S., Goldstein D.S., Tuscano J.M., Wun T., Chew H.K., Lara P.N., Kukis D.L., Natarajan A., Meares C.F., Lamborn K.R., and DeNardo G.L. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin. Cancer Res. 11 (2005) 5920-5927
241. 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J. Nucl. Med. 46 (2005) 620-633
242. 90Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin. Cancer Res. 9 (2003) 3929S-3937S